HRT Financial’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-202,847
Closed -$9.73M 5185
2026
Q1
$9.73M Buy
202,847
+126,106
+164% +$5.52M 0.02% 629
2025
Q4
$2.96M Sell
76,741
-867,910
-92% -$33.1M 0.01% 1047
2025
Q3
$33.3M Buy
944,651
+712,731
+307% +$25.8M 0.12% 101
2025
Q2
$8.36M Buy
231,920
+115,846
+100% +$3.84M 0.04% 365
2025
Q1
$3.61M Buy
116,074
+70,349
+154% +$2.23M 0.02% 567
2024
Q4
$1.17M Buy
+45,725
New +$1.21M 0.01% 999
2024
Q2
Sell
-130,188
Closed -$3.95M 2965
2024
Q1
$3.95M Buy
+130,188
New +$3.84M 0.02% 335
2023
Q4
Sell
-103,916
Closed -$2.82M 2959
2023
Q3
$2.82M Sell
103,916
-258,823
-71% -$7.69M 0.03% 475
2023
Q2
$11.2M Buy
+362,739
New +$12.3M 0.1% 129
2023
Q1
Sell
-119,689
Closed -$4.73M 3097
2022
Q4
$4.73M Buy
+119,689
New +$5M 0.07% 283
2022
Q3
Sell
-60,283
Closed -$2.53M 3398
2022
Q2
$2.53M Buy
+60,283
New +$2.47M 0.03% 480
2021
Q3
Sell
-310,887
Closed -$12.7M 3691
2021
Q2
$12.7M Buy
+310,887
New +$13.2M 0.12% 154
2020
Q3
Sell
-70,234
Closed -$3.41M 2277
2020
Q2
$3.41M Buy
+70,234
New +$3.48M 0.1% 201

Other funds holding RPRX

HRT Financial's RPRX Position: Q2 2026 in Review

HRT Financial sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 202,847 shares — an estimated $9.73M sold.

HRT Financial first reported a position in RPRX in Q2 2020 and held it in 13 quarters. The position peaked at $33.3M in Q3 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • HRT Financial reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 202,847 Royalty Pharma shares in Q2 2026, an estimated $9.73M.
  • HRT Financial first reported a position in Royalty Pharma in Q2 2020 and held it in 13 quarters.
  • HRT Financial's Royalty Pharma position peaked at $33.3M in Q3 2025.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.